UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): December 12, 2017

TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified in its charter)

Nevada	**001-36019**	**26-1434750**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

509 Madison Avenue, Suite 306, New York, New York 10022
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (212) 980-9155

Copy of correspondence to:

Michael J. Lerner, Esq.
Lowenstein Sandler LLP
One Lowenstein Drive
Roseland, NJ 07068
Tel: (973) 597-2500 Fax: (973) 597-6395

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Tonix Pharmaceuticals Holding Corp. (the "Company") updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.01 hereto and incorporated herein by reference.

Item 8.01 Other Events.

On December 12, 2017, the Company issued a press release announcing its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets). A copy of the press release is filed as Exhibit 99.02 hereto and incorporated herein by reference.

The information in this Current Report, including all exhibits, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing, and is not deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.01	Corporate Presentation by the Company for December 2017*
99.02	Press release, dated December 12, 2017, issued by Tonix Pharmaceuticals Holding Corp.*

_____

* Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

TONIX PHARMACEUTICALS HOLDING CORP.

Date: December 12, 2017

By:/s/ Bradley Saenger
Bradley Saenger
Chief Financial Officer

Exhibit 99.01

Investor Presentation

TONIX PHARMACEUTICALS

December 2017

Version P0089 12-12-17 (Doc 0303)

Cautionary Note on Forward-Looking Statements

Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain U.S. Food and Drug Administration clearances or approvals and noncompliance with its regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission (the "SEC") on April 13, 2017, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Tonix is Developing a Portfolio of Potential Treatments for Important Public Health Challenges and Diseases with Significant Unmet Needs

Tonmya®[1] (cyclobenzaprine HCl sublingual tablets) bedtime treatment for posttraumatic stress disorder (PTSD)

- Phase 3 HONOR study of Tonmya in military-related PTSD enrolling
- Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)

TNX-102 SL (cyclobenzaprine HCl sublingual tablets) bedtime treatment for Agitation in Alzheimer's (AAD)

- Pre-IND meeting held Nov 2017
- IND to be submitted 1Q2018

TNX-601 (tianeptine oxalate) daytime treatment for PTSD

- Ongoing preclinical development
- Novel salt and polymorph of an active ingredient marketed in Europe for depression with efficacy evidence in PTSD from published literature

TNX-801 (synthesized live horsepox virus) as a vaccine to prevent smallpox

- Recent New England Journal of Medicine letter[2] found a 1902 U.S. smallpox vaccine to have a genomic core 99.7% similar to horsepox
- Eligible for an FDA Priority Review Voucher (PRV) under the 21st Century Cures Act[3]

[1] FDA has conditionally accepted Tonmya as the proposed proprietary name for cyclobenzaprine HCl sublingual tablets, or TNX-102 SL, for PTSD, which is an investigational new drug and has not been approved for any indication.
[2] Schrick, L. et al. , N Engl J Med 2017; 377:1491-1492, http://www.nejm.org/doi/full/10.1056/NEJMc1707600
[3] PRV's issued upon FDA approval, based on definition of medical counter-measure drug

Products in Development



All programs owned outright with no royalties or other obligations due

¹NDA- New Drug Application; ²BLA –Biologic Licensing Application; ³Investigational New Drug Application

Tonmya (Cyclobenzaprine HCl Sublingual Tablets) for PTSD

Phase 3 HONOR study of Tonmya in military-related PTSD enrolling

- Encouraging evidence of safety and efficacy was demonstrated in Phase 2

Breakthrough Therapy designation from the FDA

- Expedited development and accelerated review are expected
- Potential to file NDA[1] based on one Phase 3 study if data are statistically persuasive

Proposed registration plan agreed to by the FDA

- Additional nonclinical safety and clinical abuse potential studies are not required

Patent protection through 2034 in U.S.[1]

- Composition of matter patent for eutectic, required for transmucosal delivery of cyclobenzaprine

Novel mechanism targets sleep quality

- Memory processing during sleep is important to recovery

[1] U.S. Patent No. 9,636,408 for eutectic proprietary Protectic™ formulation

Phase 3 HONOR Study in PTSD Enrolling

To confirm Phase 2 AtEase findings in military-related PTSD:

- Larger adaptive-design study
- Enrollment started in 1Q 2017

Tonmya once-daily at bedtime
5.6 mg *N ~ 275 (140**)*

Placebo once-daily at bedtime
*N ~ 275 (140**)*

- **General study characteristics:**
- Randomized, double-blind, placebo-controlled, entrance CAPS-5* ≥ 33
- One unblinded interim analysis (IA) by an independent data monitoring committee at 50% randomized
- IA (N ~275) for efficacy stop, continuation as planned or sample size adjustment
- Potential to enroll 550 participants
- Multicenter study - approximately 35-40 U.S. clinical sites
- **Primary efficacy endpoint:**
- Mean change from baseline in total CAPS-5 at week 12 compared between Tonmya 5.6 mg and placebo

12 weeks → ····· *open-label extension*

3Q 2018 - IA outcome anticipated
4Q 2018 – topline data anticipated, if 550 participants are studied

*CAPS-5 = Clinician-Administered PTSD Scale for DSM-5
***Interim analysis*

Breakthrough Therapy Designation

FDA granted Tonmya Breakthrough Therapy designation – reported December 19, 2016

- PTSD is a serious condition
- Tonmya has potential advantages over existing therapies in military-related PTSD

Benefits of Breakthrough Therapy designation

- Eligibility for priority review of the NDA within 6 months instead of 10 months
- Option to submit completed portions of the NDA for rolling review
- An organizational commitment involving FDA's senior managers to accelerate the development and approval process, an opportunity to compress development time

NDA filing based on HONOR study is possible if results are statistically persuasive

- Discussed at March 9, 2017 Initial Cross-disciplinary Breakthrough Meeting with the FDA

No Recognized Abuse Potential in Clinical Studies

Active ingredient is cyclobenzaprine, which is structurally related to tricyclic antidepressants

- Cyclobenzaprine interacts with receptors that regulate sleep quality: 5-HT_{2A}; α_1-adrenergic and histamine H_1 receptors
- Cyclobenzaprine does **NOT** interact with the same receptors as traditional hypnotic sleep drugs, benzodiazepines or non-benzodiazepines that are associated with retrograde amnesia
- Cyclobenzaprine-containing product was approved 40 years ago and current labeling (May 2016) indicates no abuse or dependence concern

Tonmya NDA can be filed without abuse assessment studies

- Discussed at March 9, 2017 Initial Cross-disciplinary Breakthrough Meeting with the FDA

TNX-102 SL Intellectual Property – U.S. Protection until 2034

Composition of matter (eutectic)

- U.S. Patent No. 9,636,408 issued May 2, 2017 by U.S. Patent and Trademark Office
  - Protection expected to 2034
- Additional claims and jurisdictions pending

Pharmacokinetics (PK)

- Patent applications filed
  - Protection expected to 2033

Method of use for active ingredient cyclobenzaprine

- European Patent No. 2,501,234 issued September 13, 2017 by European Patent Office
  - Protection expected to 2030
- Additional claims and jurisdictions pending

Proprietary Cyclobenzaprine Hydrochloride Eutectic Mixture Stabilizes Sublingual Tablet Formulation



[1] U.S. Patent issued May 2, 2017

TNX-102 SL: Sublingual Formulation is Designed for Bedtime Administration

TNX-102 SL: Proprietary sublingual formulation of cyclobenzaprine (CBP) with transmucosal absorption

- Innovation by design with patent protected CBP/mannitol eutectic
- Rapid systemic exposure
- Increases bioavailability during sleep
- Avoids first-pass metabolism
- Lowers exposure to long-lived active major metabolite, norcyclobenzaprine (norCBP)

CBP undergoes extensive first-pass hepatic metabolism when orally ingested

- Active major metabolite, norCBP[1]
  - Long half-life (~72 hours)
  - Less selective for target receptors (5-$HT_{2A,}$ α_1-adrenergic, histamine H_1)
  - More selective for norepinephrine transporter

[1] Daugherty et al., Abstract 728, Society of Biological Psychiatry 70th Annual Scientific Convention, May 14-16, 2015, Toronto Ontario, Canada

Tonmya: Novel Mechanism Targets Sleep Quality for Recovery from PTSD

PTSD is a disorder of recovery

- Most people exposed to extreme trauma recover over a few weeks
- In PTSD, recovery process impeded due to insufficient sleep-dependent memory processing

Memory processing is essential to recovery

- Vulnerability to memory intrusions and trauma triggers remains if no consolidation of new learning (extinction)

Tonmya targets sleep quality[1]

- Cyclobenzaprine interacts with receptors that regulate sleep quality: strongly binds and potently blocks 5-HT_{2A}, α_1-adrenergic and histamine H_1 receptors, permissive to sleep-dependent recovery processes

[1] Daugherty et al., Abstract 728, Society of Biological Psychiatry 70th Annual Scientific Convention, May 14-16, 2015, Toronto Ontario, Canada

What are the Symptoms of PTSD?

Symptoms of PTSD fall into four clusters:

1. Intrusion (aversive memories, nightmares, flashbacks)
2. Avoidance (avoiding persons, places or situations)
3. Mood/cognitions (memory block, emotional numbing, detachment from others)
4. Hyperarousal (anxiety, agitation & sleep disturbance)

CAPS-5 is used to assess symptom severity and treatment effect

- Recognized as the standard for rating PTSD severity in clinical trials
- Takes into account all four symptom clusters

What are the Consequences of PTSD?

Consequences:

- Impaired daily function and substantial interference with work and social interactions
- Reckless or destructive behavior
- Increased health care utilization and greater medical morbidity

PTSD as a risk factor for:

- Depression
- Alcohol or substance abuse
- Absenteeism/unemployment
- Homelessness
- Violent acts
- Suicidal thoughts and suicide

PTSD: U.S. Prevalence and Index Traumas

A chronic response to traumatic event(s)

- A majority of people will experience a traumatic event at some point in their lifetime[1]
  - 20% of women and 8% of men in the U.S. who experience significant trauma develop PTSD[1]
  - *Lifetime prevalence:* 6.8%[2] (~ 17.0 million adults in the U.S.)
    - Persistent - >1/3 fail to recover, even after several years following the trauma[2]
  - *Twelve month prevalence:* *U.S.* 3.5% (~ 8.6 million adults)[3]
    EU 2.3% (~10.0 million adults)[4]

Most common forms of trauma[1]

- Witnessing someone being badly injured or killed
- Natural disaster
- Life-threatening accident
- Sexual or physical assault

[1] Kessler et al., Arch Gen Psychiatry 1995; 52:1048
[2] Kessler et al., Arch Gen Psychiatry 2005; 62:593
[3] Kessler et al., Arch Gen Psychiatry 2005; 62:617; Prevalence rate of 3.5% applied to U.S. Census estimate of 247 million U.S. adult (≥18) population in 2015 (www.census.gov/quickfacts/table/PST045215/00)
[4] The European Union Market Potential for a New PTSD Drug. Prepared for Tonix Pharmaceuticals by Procela Consultants Ltd, September 2016

PTSD Prevalence and Market Characteristics

Prevalent Population (U.S.)
~8.6 million[1]



Diagnosed population

Large population (~1.8 million)
Majority receive drug treatment
- Civilians: ~75%[2]
- Veterans: ~80%[4]

[1] Kessler, et al., 2005; Prevalence rate of 3.5% applied to U.S. Census estimate of 247 million U.S. adult (≥18) population in 2015 (www.census.gov/quickfacts/table/PST045215/00)
[2] IMS Consulting, *Market Sizing & Treatment Dynamics: Post-Traumatic Stress Disorder (PTSD) Patients"*, 2016
[3] Bowe and Rosenheck, 2015 (638,451 veterans diagnosed with PTSD in the VA in fiscal year 2012 across all medical centers)
[4] Bernardy et al., 2012 (80% of veterans diagnosed with PTSD had at least one medication from the Clinical Practice Guidelines)

What Drug Classes are Used to Treat PTSD?

Market highly fragmented, with benzodiazepines widely prescribed (but not indicated)[1]

- Multiple medications per patient (or "Polypharmacy") is the norm
  - Approximately 55% of patients receive a benzodiazepine, and 53% receive a selective serotonin reuptake inhibitor (SSRI)
- SSRIs are the only FDA-approved drug class

Estimated PTSD Market Volume (Civilian Population Only) ~14.1 million TRx*[2]



* TRx = Total prescriptions

[1] VA/DoD Clinical Practice Guideline for the Management of Post-Traumatic Stress, Version 2, 2010

[2] IMS Consulting, *Market Sizing & Treatment Dynamics: "Post-Traumatic Stress Disorder (PTSD) Patients"*, 2016

PTSD: Not Well-Served by Approved Treatments

FDA-approved SSRIs, paroxetine and sertraline, have not shown efficacy in military-related PTSD

Majority of patients unresponsive or intolerant to current treatments

- Side effects relating to sexual dysfunction (particularly in males) and sleep are commonly reported

Characteristics of drug therapy that would be compatible and complementary with behavioral therapy

- Lack of retrograde amnesia (e.g., unlike off-label use of benzodiazepines and non-benzodiazepines)
- Lack of interference on sleep (e.g., unlike approved SSRIs)

Why Initially Target Military-Related PTSD?

Military-related PTSD not well-served by existing FDA-approved therapies

- ***No clear treatment response observed in U.S. military population***

  Sertraline: failed to show efficacy in a large multicenter trial in U.S. military (placebo numerically better)[1]
  Paroxetine: no large trials conducted with predominantly military trauma

- **Inconsistent treatment response observed in males**

  Sertraline: FDA-conducted post-hoc analysis concluded no effect for male civilian subgroup[2]
  Paroxetine: no sex-related difference in treatment outcomes[3]

- **Important tolerability issues with SSRIs in this population**

  Sexual dysfunction[2,3]
  Insomnia[2,3]
  SSRI withdrawal syndrome[4]

[1] Friedman et al., J Clin Psychiatry 2007; 68:711
[2] Zoloft Package Insert, August, 2014
[3] Paxil Package Insert, June, 2014
[4] Fava et al., Psychother Psychosom 84:72-81, 2015

High Prevalence of PTSD Among Combat Veterans

3-9%
General population[1]

19-31%
Vietnam veterans[2]

>19%
Operation Enduring Freedom (OEF; Afghanistan) / Operation Iraqi Freedom (OIF) veterans / Operation New Dawn (OND)[3]

8.6 million American adults affected[1]

Women more likely to develop than men[1]

Susceptibility may **run in families**[1]

[1] Kessler et al., *Arch Gen Psych* 2005; Prevalence rate of 3.5% applied to U.S. Census estimate of 247M U.S. adult (≥18) population in 2015 (www.census.gov/quickfacts/table/PST045215/00); [2]Norris, *PTSD Res Quar*. 2013; [3]*Analysis of VA Health Care Utilization among Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn Veterans, from 1st Qtr FY 2002 through 2nd Qtr FY 2015,* Washington, DC; Among 1.9M separated OEF/OIF/OND veterans, 1.2M have obtained VA healthcare; 685k evaluated by VA with possible mental disorder, and 379k diagnosed with PTSD.

Growing Economic and Social Burden to Care for Veterans with PTSD

Health care costs associated with PTSD for OEF/OIF/OND veterans:

Direct costs

$3,000-5,000
per patient per year for OEF/OIF Veterans[1]

~ 1.9M Veterans out of 2.7M
Service members deployed between 10/1/2001 and 3/31/2015[3]

Indirect costs

$2-3 billion
estimated yearly cost to society[2]

Families, social care agencies, schools, employers, welfare system[2]

[1] CBO Report 2012; [2] Tanielan, *Invisible Wounds of War*. 2005; [3] *Analysis of VA Health Care Utilization among Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn Veterans, from 1st Qtr FY 2002 through 2nd Qtr FY 2015,* Washington, DC; OEF/OIF/OND, Operations Enduring Freedom, Iraqi Freedom and New Dawn.

Phase 2 AtEase Study in Military-Related PTSD



- Randomized, double-blind, placebo-controlled trial in military-related PTSD
- Efficacy analysis from 231 patients; 24 U.S. clinical sites
- Enrolled patients with baseline CAPS-5 ≥ 29
- **Primary Efficacy Analysis:**
  - Difference in CAPS-5 score change from baseline between Tonmya 2.8 mg and placebo at week 12
- Key Secondary Measures:
  - PROMIS Sleep Disturbance, CGI-I, SDS

Results of Phase 2 AtEase Study in Military-Related PTSD

Tonmya 5.6 mg showed clinical benefit in military-related PTSD

- CAPS-5 scale, was statistically significant by Mixed-effect Model Repeated Measures, or MMRM, with Multiple Imputation, or MI, analysis (p-value = 0.031)
- Dose-effect on multiple efficacy and safety measurements

Well tolerated

- No serious adverse events (AE) related to treatment
- The most common AEs were local site-administration reactions, including mild and transient tongue numbness

AtEase Study Demographics and Characteristics

93% of the randomized patients were male

98% had trauma during military service

Deployed an average of 2.3 times

Mean time since index trauma was 7 years

Race and ethnicity generally consistent with U.S. military distribution

Similar baseline CAPS-5 scores and MADRS[1] scores across treatment arms

Current Major Depressive Disorder 14% by MINI 7.0[2]

[1] MADRS, Montgomery-Åsberg Depression Rating Scale
[2] MINI 7.0, Mini-International Neuropsychiatric Interview, Version 7

AtEase Study: Traumas Associated with PTSD



*Some patients experienced more than one trauma

AtEase Study – Summary of Primary and Secondary Analyses (week 12)

Assessment	Domain	Analysis	p-Values	
			2.8 mg (N=90)	5.6 mg (N=49)
CAPS-5	Total	MMRM (Primary Analysis)	0.259^	0.053
	Total	MMRM with Multiple Imputation	0.211	0.031*
	Total	MMRM w/ Hybrid LOCF/BOCF	0.172	0.037*
	Total	ANCOVA	0.090	0.038*
CAPS-5 clusters/items	Arousal & Reactivity cluster (E)	MMRM	0.141	0.048*
	Sleep item (E6)	MMRM	0.185	0.010*
	Exaggerated Startle item (E4)	MMRM	0.336	0.015*
CGI-I	Responders	Logistic Regression	0.240	0.041*
PGIC	Mean score	MMRM	0.075	0.035*
Sheehan Disability Scale	Work/school item	MMRM	0.123	0.050*
	Social/leisure item	MMRM	0.198	0.031*

BOCF, baseline observation carried forward; CGI-I, Clinical Global Impression - Improvement scale; LOCF, last observation carried forward; MMRM, mixed model repeated measures; PGIC, Patient Global Impression of Change
^Primary analysis p-value not significant comparing Tonmya 2.8 mg versus placebo
*p<0.05

AtEase Study Results: Primary Endpoint
CAPS-5 Total Score by MMRM with MI#



#Primary analysis MMRM (mixed-effect model repeated measures), *p=0.031, comparing placebo and Tonmya 5.6 mg, *p<0.05, comparing placebo and Tonmya 2.8 mg, by MMRM with MI; CAPS-5, Clinician Administered PTSD Scale for DSM-5; LS Mean, least squares mean

AtEase Study: Safety and Tolerability Profile

No serious adverse events reported with Tonmya deemed related to treatment

Systemic Adverse Events*	Placebo (N=94)	Tonmya 2.8 mg (N=93)	Tonmya 5.6 mg (N=50)
Somnolence	6.4%	11.8%	16.0%
Dry Mouth	10.6%	4.3%	16.0%
Headache	4.3%	5.4%	12.0%
Insomnia	8.5%	7.5%	6.0%
Sedation	1.1%	2.2%	12.0%
Administration Site Reactions*			
Hypoaesthesia oral	2.1%	38.7%	36.0%
Paraesthesia	3.2%	16.1%	4.0%
Glossodynia	1.1%	3.2%	6.0%

Trial completion rates: 73% placebo; 79% Tonmya 2.8 mg; 84% Tonmya 5.6 mg

*at rates of >5% in either drug-treated arm, Safety population N=237

Assessing CAPS-5 Entry Threshold in AtEase

Score of ≥29 on CAPS-5 (20 items) required at screening and baseline

- >50 on prior versions of CAPS (17 items) typical in previous drug registration trials
- Extrapolation from prior versions of CAPS: ((50/17 items)/2) x 20 items = 29.4

***Post-hoc* analysis to impute CAPS for DSM-IV (iCAPS-IV) scores for each subject**

- Baseline iCAPS-IV score calculated by summing 17 items in common with CAPS-5 and multiplying by two (for 0-8 intensity + frequency rather than 0-4)
- 4.3% of the sample had baseline iCAPS-IV of ≤ 50
- Choosing CAPS-5 ≥33 results in all iCAPS-IV > 50
- 80% of mITT had baseline CAPS-5 of ≥ 33

Primary analysis of AtEase was run for subgroup with baseline CAPS-5 ≥ 33

AtEase Retrospective Analysis:
Effect Sizes for Total CAPS-5 and Cluster Scores

Effect sizes calculated for total CAPS-5 and clusters for patients with entry CAPS-5 ≥33

- Larger effect size, in moderate range of 0.5, for total CAPS-5 and intrusion and hyperarousal clusters

Effect Sizes in Tonmya 5.6 mg Subgroup with entry CAPS-5 ≥33



* MMRM, mixed-effect model repeated measures, p<0.05

CAPS-5 Change in Subgroup with entry CAPS-5 ≥33



** p<0.01, * p<0.025, Tonmya 5.6 group with placebo, MMRM with multiple imputation (MI); *p=0.018, Tonmya 2.8 mg group with placebo, MMRM with MI

Based on findings of post-hoc imputed CAPS, a baseline CAPS-5 score ≥33 was set as PTSD severity inclusion criterion in Phase 3 HONOR study

AtEase Study Retrospective Analysis:
Sustained Remission in Subgroup with Entry CAPS-5 ≥33

Remission is more clinically meaningful if it is sustained

In order to look at sustained remission:

- Determined rates of participants who met remission status at *both* Week 8 and Week 12

21% of the Tonmya 5.6 mg participants met for sustained remission v. 5% of placebo (p=0.02)



Remission = Loss of Diagnosis and CAPS-5 < 11
Asterisk and hashmark represent pairwise comparisons between Tonmya and Placebo; #p=0.08, Odds Ratio 3.01 (0.89, 10.18)
*p=0.02, Odds Ratio 4.60 (1.27, 16.66); logistic regression

TNX-102 SL – Multi-Functional Mechanism Involves Antagonism at 3 Neuronal Receptors

Active ingredient is cyclobenzaprine, interacts with 3 receptors

- Antagonist at 5-HT_{2A} receptors
  - Similar activity to trazodone and Nuplazid® (pimivanserin)
- Antagonist at α_1-adrenergic receptor
  - Similar activity to prazosin
- Antagonist at histamine H_1 receptors
  - Similar activity to Benadryl® (diphenhydramine) and hydroxyzine

Multi-functional activity suggests potential for other indications

- TNX-102 SL was developed for the management of fibromyalgia (Phase 3)
- Sleep quality is a problem in other conditions

Cyclobenzaprine Effects on Nerve Cell Signaling

Cyclobenzaprine is a multi-functional drug - SNARI

- inhibits serotonin and norepinephrine reuptake
- blocks serotonin $5HT_{2a}$ and norepinephrine α_1 receptors



SNARI = Serotonin and Norepinephrine receptor Antagonist and Reuptake Inhibitor

Comparison of Tonmya with Drugs Used Off-Label in PTSD

Trazodone (disordered sleep), prazosin (night terrors)

- Trazodone inhibits serotonin $5HT_{2a}$ receptors and serotonin reuptake (SARI)
- Prazosin blocks norepinephrine α_1 receptors



SARI – Serotonin Receptor Antagonist & Reuptake Inhibitor (Stahl SM, CNS Spectrums, 2009;14:536).

Opportunities to Expand to Other Indications

Role of sleep disturbance more established in common psychiatric and neurological/pain disorders

- Recognized as a core symptom of many of these disorders
- Traditional sleep medications, which increase sleep quantity, may not provide benefit (benzodiazepines in major depression) or are contraindicated (benzodiazepines in PTSD)

Psychiatric Disorders

- Stress Disorders (PTSD)
- Mood Disorders
- Anxiety Disorders

Psychiatric Symptoms of Neurological Disorders

- Agitation in Alzheimer's
- Psychosis in Parkinson's, Alzheimer's and other dementias

Chronic Pain States

- Chronic wide-spread pain (fibromyalgia)
- Osteoarthritis

Growing recognition that there is a constellation of disorders where sleep disturbances may have a role in the pathophysiology (cardiovascular, metabolic, neurologic)

- Homeostatic role of sleep quality *in several disorders*

TNX-102 SL – Multiple Potential Indications

Management of Fibromyalgia – chronic pain condition

- Tonix's Phase 3 program was halted after near miss in Phase 3 at low dose (2.8 mg) – half the dose being developed for PTSD
- Imbalance in "withdrawal of consent" led to statistical miss on responder analysis – A few TNX-102 SL treated patients "moved out of state"
- Average pain improvement (secondary endpoint) after 12 weeks of treatment showed statistical significance ($P < 0.05$)
- TNX-102 SL showed an improvement in sleep quality in Phase 2 and 3 trials in fibromyalgia

Agitation in Alzheimer's Disease

- FDA pre-IND meeting held Nov, 2017
- FDA agrees Tonix has sufficient data to file an IND for a Phase 2/potential pivotal efficacy study

What is Agitation in Alzheimer's Disease?

Agitation is one of the most distressing and debilitating of the behavioral complications of Alzheimer's disease

- Includes emotional lability, restlessness, irritability and aggression[1]

Link between agitation in disturbed sleep and agitation in Alzheimer's[1-3]

- Agitation is commonly diurnal ("sundowning")

Prevalence

- Agitation is likely to affect more than half of the 5.3 million Americans who currently suffer from moderate to severe Alzheimer's disease, and this number is expected to nearly triple by 2050[4]

[1]Rose, K.et al. (2015). *American Journal of Alzheimer's Disease & Other Dementias*, *30*:78
[2]Shih, Y. H., et al. (2017). *Journal of the American Medical Directors Association*, *18*, 396.
[3]Canevelli, M., et al. (2016). *Frontiers in medicine*, *3*.
[4]The Alzheimer's Association, 2017 Alzheimer's Disease Facts and Figures: https://www.alz.org/facts/

Consequences of Agitation in Alzheimer's Disease

Outcomes

- Agitation is associated with significant negative outcomes for Alzheimer's patients and their caregivers

Common reason for confinement

- Development of agitation, or its worsening, is one of the most common reasons for patients having to transition from lower- to higher levels of care (nursing homes and other long-term care settings)[1]

Cost

- The presence of agitation nearly doubles the cost of caring for patients with Alzheimer's disease, and agitation is estimated to account for more than 12% of the healthcare and societal cost of Alzheimer's disease, which is currently estimated to be $256 Billion for the year 2017 in the United States[1]

[1]The Alzheimer's Association, 2017 Alzheimer's Disease Facts and Figures: https://www.alz.org/facts/

Agitation in Alzheimer's Disease – Potential New Indication for TNX-102 SL

Successful pre-IND meeting in November, 2017

- IND planned 1Q2018 to support a Phase 2 efficacy study

Significant unmet need

- No FDA approved drugs for the treatment of agitation in Alzheimer's

Mechanism of improving sleep quality

- Sleep disturbance is a significant and common symptoms in Alzheimer's

Pharmacological advantages outweigh potential concerns of using TNX-102 SL in treating agitation in Alzheimer's disease

- Blocks 3 receptors, not just one (e.g., 5-HT_{2A})
- Anti-muscarinic (M1) effect in patients on anticholinergics (e.g., donepezil and rivastigmine) possibly reduced with lower sublingual dose

TNX-102 SL for Agitation in Alzheimer's – Regulatory Status and Registration Strategy

FDA confirmed no additional study is needed prior to IND submission

- Pre-IND meeting established open dialogue with the FDA on pivotal clinical study design and efficacy endpoints to support product registration

Planned Phase 2 study IND submission in 1Q2018

- Proposed Phase 2 IND study can potentially serve as a pivotal efficacy study

Approval of TNX-102 SL in agitation in Alzheimer's disease Efficacy Supplement (sNDA[1]) may be leveraged from the PTSD development program and supported by Initial NDA approval for PTSD

[1]Supplemental New Drug Application

Scientific Rationale for Developing TNX-102 SL for Agitation in Alzheimer's Disease

Connection between Sleep Disturbance and Agitation

- Agitation in Alzheimer's Disease is associated with sleep disturbance[1,2]

Supported by Potential Mechanism of Action

- TNX-102 is a multifunctional agent including antagonism of 5-HT_{2A}, α_1 adrenergic and histamine H_1 receptors
- Certain 5-HT_{2A} antagonists have shown clinical efficacy against agitation in dementia including trazodone[3], and mirtazapine[4]
- The α_1 adrenergic antagonist prazosin has shown efficacy in the treatment of agitation in dementia[5]
- The H_1 antagonist hydroxyzine had historical use in treating agitation in dementia

[1]Bachmen and Rabins, 2006
[2]Rose, K.et al. (2015). *American Journal of Alzheimer's Disease & Other Dementias*, *30*:78
[3]Teri et al., 2000
[4]Cakir et el., 2008
[5]Wang et al., 2009

TNX-102 SL Potentially Addresses Some of the Challenges in Treating Agitation in Alzheimer's

Sublingual route of administration (no swallowing)

- Swallowing can be an issue for a significant number of Alzheimer's patients

Low dose taken daily at bedtime

- Potentially minimize daytime anticholinergic side effects → improved tolerability

Role of sleep in clearing debris from the brain

- Animal studies have shown the brain clears debris from the brain during sleep including toxic proteins associated with Alzheimer's progression[1]

[1]T Xie L, et al. Science. (2013);342(6156):373

Agitation in Alzheimer's – Competitive Landscape of Select Drugs in Development

Competitive landscape

- 5HT2A Antagonists/inverse agonists
  - Pimavanserin (Acadia)
  - Nelotanserin (Axovant)
- Atypical Antipsychotics (also have 5HT2A antagonism)
  - Rexulti® brexpiprazole (Otsuka/Lundbeck)
  - Lumateperone (InterCellular)
- Dextromethorphans – believed to act as SSRI, glutamate/NMDA and sigma-1 receptor modulators
  - Deudextromethorphan (Avenir/Otsuka) - deuterated version of Nuedexta®
  - Dextromethorphan/buproprion (Axesome)

TNX-102 SL uniquely designed for bedtime dosing and transmucosal absorption

- Maximize drug exposure during sleep → improving sleep quality
- Other 5-HT_{2A} antagonists not designed for bedtime dosing

Products in Development



All programs owned outright with no royalties or other obligations due

¹NDA- New Drug Application; ²BLA –Biologic Licensing Application; ³Investigational New Drug Application

TNX-601 (Tianeptine Oxalate): A Potential Clinical Candidate for PTSD

Pre-IND Candidate

- Targeted as a 1st line monotherapy for **PTSD**: oral formulation for **daytime dosing**
  - ✓ **Leverages expertise in PTSD (clinical and regulatory experience, market analysis, etc.)**
  - ✓ **Mechanism of Action (MOA) is different from Tonmya**
- Tianeptine sodium (amorphous) has been approved in EU, Russia, Asia and Latin America for depression since 1987 with established post-marketing experience
- Identified new oxalate salt polymorph with improved pharmaceutical properties ideal for reformulation
- **Filed patent application on novel salt polymorph**
- Issued patent on steroid-induced cognitive impairment and memory loss issues

Targeting a Public Health Challenge

- **Clinical evidence for PTSD**
- Several studies have shown tianeptine to be active in the treatment of PTSD[1-4]

[1] Frančišković T, et al. Psychiatr Danub. 2011 Sep;23(3):257-63. PMID: 21963693
[2] Rumyantseva GM and, Stepanov AL. Neurosci Behav Physiol. 2008 Jan;38(1):55-61. PMID: 18097761
[3] Aleksandrovskiĭ IA, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(11):24-9. PMID: 16329631 [Russian]
[4] Onder E, et al. Eur Psychiatry. 2006 (3):174-9. PMID: 15964747

Structural Comparison: TNX-102 and TNX-601

Cyclobenzaprine and tianeptine share structural similarities with classic tricyclic antidepressants (TCAs) and to each other, but each has unique pharmacological properties

- Tianeptine has a 3-chlorodibenzothiazepine nucleus with an aminoheptanoic side chain

Tianeptine leverages Tonix's expertise in the pharmacology and development of tricyclics



TNX-102 (cyclobenzaprine HCl)



TNX-601 (tianeptine oxalate)

TNX-601: A Potential Clinical Candidate for PTSD

The active pharmaceutical ingredient (API) is a novel oxalate salt of tianeptine

- Shares structural features with tricyclic antidepressants, but has unique pharmacological and neurochemical properties[1]
- GMP synthesis developed

Mechanism of Action

- **Tianeptine modulates the glutamatergic system indirectly**
  - Does not have significant affinity (K_i>10μM) for NMDA[2] or AMPA[3] receptors
- **Tianeptine is a weak μ-opioid receptor (MOR) agonist**
  - Controlled substance in France, Bahrain and Singapore
- **Tianeptine has been shown to oppose deleterious effects of chronic stress on brain structure and plasticity**

Important Characteristics of TNX-601

- **TNX-601: Novel oxalate salt and polymorph of tianeptine**
  - Improved stability, consistency and manufacturability
  - Benefited from human experience established in ex-U.S. approved countries
  - Potential safety and efficacy evidence in published PTSD studies[4-7]
- **5 year Hatch-Waxman exclusivity for first time approval in the U.S.**
- **Patent filed on novel oxalate salt and polymorph**

[1]McEwen, Bruce S., et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Molecular psychiatry 2010; 15.3: 237-249
[2]NMDA; N-methyl-D-aspartate
[3]AMPA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
[4]Frančišković T, et al. Psychiatr Danub. 2011 Sep;23(3):257-63. PMID: 21963693
[5]Rumyantseva GM and, Stepanov AL. Neurosci Behav Physiol. 2008 Jan;38(1):55-61. PMID: 18097761
[6]Aleksandrovskiĭ IA, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(11):24-9. PMID: 16329631 [Russian]
[7]Onder E, et al. Eur Psychiatry. 2006 (3):174-9. PMID: 15964747

TNX-801 (Synthesized Live Horsepox Virus): A Potential Smallpox-Preventing Vaccine

Pre-IND Candidate

Potential improvement over current methods for biodefense against smallpox

- ✓ Leverages government affairs effort
- ✓ Collaboration with Professor David Evans and Dr. Ryan Noyce at University of Alberta
- ✓ Protective vaccine activity in mice has been demonstrated
- ✓ Patent application on novel vaccine submitted

Regulatory strategy

- FDA's "Animal Rule" can be applied to establish human efficacy
- Good Manufacturing Practice (GMP) virus in development for human safety study

Targeting a Public Health Issue

Material threat medical countermeasure under 21st Century Cures Act

- Qualifies for receiving **Priority Review Voucher** on approval
  - ✓ **Priority Review Vouchers have no expiration date, are transferrable and have sold for ~$125 M**
- ACAM2000™ vaccine developed by Acambis was acquired by Sanofi in 2008 for $513 M
  - ✓ **ACAM2000 was sold to U.S. Strategic National Stockpile[1]**

[1] Nalca, A et al. Drug design, development and Therapy: 4:71-79 (2010)

TNX-801 (Synthesized Live Horsepox Virus): A Potential Smallpox-Preventing Vaccine

Synthesis from sequence of a 1976 Mongolian isolate[1]

In mice, TNX-801 behaved like attenuated vaccinia virus

- Vaccinia is the term used to classify the live poxviruses that are used as smallpox vaccines, including ACAM2000, which is the latest smallpox vaccine approved in the U.S.

How is HPXV related to modern vaccines?

- Multiple sources[2-4] indicate that the smallpox vaccine discovered by Dr. Edward Jenner in the early 19th century was either HPXV or a very similar virus and that vaccinia vaccines are derived from this ancestral strain
- A 1902 U.S. smallpox virus was found to be highly similar (99.7% similarity in core genome[5]) to HPXV sequence from the 1976 Mongolian isolate
- Horsepox is now believed to be extinct[4]

[1] Tulman et al., Journal of Virology, 2006; 80(18): 9244-9258
[2] Qin et al., Journal of Virology, 2011; 85(24):13049-13060
[3] Medaglia et al., Journal of Virology, 2015; 89(23):11909-11925
[4] Esparza J. Veterinary Record. 2013; 173: 272-273
[5] Schrick, L. et al. , N Engl J Med 2017; 377:1491-1492. http://www.nejm.org/doi/full/10.1056/NEJMc1707600

Horsepox – May Have Better Tolerability as a Smallpox Preventing Vaccine?

Horsepox is caused by HPXV and is characterized by mouth and skin eruptions

HXPV isolate from the 1976 outbreak later sequenced

Modern smallpox vaccines are associated with cardiotoxicity[1]

- May have acquired undesirable properties over long period of cultivation

HPXV has potential for slower proliferation or decreased toxicity[2]

[1] Engler RJM et al., PloS ONE 10(3): e0118283. doi:10.1371/journal.pone.0118283 (2015)
[2] Tonix data (unpublished)

A Better Smallpox-Preventing Vaccine is Important and Necessary Today

Smallpox was eradicated as a result of global public health campaigns

No cases of naturally-occurring smallpox have been reported since 1977

Accidental or intentional transmission of smallpox does not require a natural reservoir

Stockpiles of smallpox-preventing vaccines are currently maintained and refreshed in case of need

TNX-801: A Potential Medical Countermeasure

21st Century Cures Act (2016), Section 3086

- Encouraging treatments for agents that present a national security threat

Medical countermeasures are drugs, biologics (vaccines) or devices intended to treat:

- Biological, chemical, radiological, or nuclear agents that present a national security threat
- Public health issues stemming from a naturally occurring emerging disease or a natural disaster

New Priority Review Voucher program for "Material Threat Medical Countermeasures"

- Priority Review Voucher may be transferred or sold

TNX-801 (Synthesized Live Horsepox Virus): A Potential Smallpox-Preventing Vaccine

Synthesized live virus HPXV TNX-801

- Shares structural characteristics with vaccinia-based vaccines
- Unique properties in cell culture and mice experiments suggest lower toxicity
- Smallpox has a ~30% mortality rate in vaccine-naïve populations

Mechanism of Action

Live virus vaccines stimulate cross-reactive immunity

- Protects from consequences of infection with smallpox agent
- Renders recipient "immune"
- Provides additional protection of non-immunized population

Important Benefits of TNX-801

Potential safety advantage over existing vaccines

- Cardiotoxicity limits use of existing vaccines

Exclusivity

- Patent application filed on novel virus composition
- Anticipate 12 years exclusivity

Vaccination Against Smallpox

Ongoing vaccination of U.S. troops

- Troops on the Korean Peninsula

Threat of smallpox re-introduction

- Strategic National Stockpile & public health policy

Re-emergence of monkey pox[1]

- Believed to resurgent because of vaccinia-naïve populations in Africa
- Multiple U.S. operations ongoing in Africa

[1]Nda- Isaiah, J. Nigeria: Monkey Pox Scourge Spreads to Seven States. All Africa. 12 OCTOBER 2017, HTTP://ALLAFRICA.COM/STORIES/201710120177.HTML

Proposed Evolution of Vaccinia Vaccines

Postulated Divergence of Historical Strains of Vaccinia



IHD-J=International Health Department-Japan
LIVP=Lister Vaccine Strain
NYCBH=NeW York City Board of Health
RPXV=Rabbitpox Virus
WR=Western Reserve

Figure Adapted from Qin et al. *Journal of Virology*. 2015;89(3):1809-1824.

Proposed Evolution of Vaccinia Vaccines

Relationship to Smallpox Incidence and Eradication



*Rough approximation (not data derived)

Jenner's Vaccine – Motivation to Study HPXV

Vaccination protects against smallpox – both individuals and populations

- Eradication based on Jenner's vaccine

Vaccination can protect AFTER infection

- Vaccinia can be administered 1-3 days after infection

Vaccination protects unvaccinated people in a population

- "Wetting the forest"

Vaccination is cost effective

- Replication-effective live virus vaccines can be manufactured and administered for large scale use

New synthetic biology technology and new understanding of vaccinia evolution have provided a potentially safer vaccine

Financial overview

NASDAQ: TNXP	
Cash, cash equivalents, and marketable securities reported at September 30, 2017	$29.3 million
Gross proceeds from sale of common stock under purchase agreement with Lincoln Park Capital Fund, LLC through December 11, 2017	$1.1 million
Shares outstanding as of December 11, 2017	7.8 million

Management Team

Seth Lederman, MD
President & CEO

Gregory Sullivan, MD
Chief Medical Officer

Bradley Saenger, CPA
Chief Financial Officer

Jessica Morris
EVP, Operations

Board of Directors

Seth Lederman, MD Chairman	**Donald Landry, MD, PhD** Chair of Medicine, Columbia University
Margaret Smith Bell Standard Life Investments, Putnam Investments, State Street Research	**Ernest Mario, PhD** ALZA, Glaxo, Reliant Pharma
Stuart Davidson Labrador Ventures, Alkermes, Combion	**Charles Mather** BTIG, Janney, Jefferies, Cowen, Smith Barney
Patrick Grace Apollo Philanthropy, WR Grace, Chemed	**John Rhodes** NYSERDA, NRDC, Booz Allen Hamilton
Samuel Saks, MD Jazz Pharma, ALZA, Johnson & Johnson	

Milestones – Recently Completed and Upcoming

Tonmya – Posttraumatic Stress Disorder

☑	May 2016	Reported results from Phase 2 AtEase study
☑	August 2016	End-of-Phase 2 meeting with FDA - Proposed Phase 3 clinical and NDA plan accepted
☑	December 2016	Breakthrough Therapy designation granted by FDA
☑	January 2017	FDA concurrence with Phase 3 HONOR study design in military-related PTSD
☑	1Q 2017	Initial Cross-disciplinary Breakthrough Meeting with FDA
☑	1Q 2017	Commenced enrollment of HONOR study
☑	2Q 2017	U.S. Patent No. 9,636,408 issued for eutectic formulation of Tonmya
☑	3Q 2017	European Patent No. 2,501,234 issued for cyclobenzaprine method of use
☐	3Q 2018	Anticipated interim analysis of HONOR study in ~275 randomized participants
☐	4Q 2018	Anticipated topline results of HONOR study in 550 participants (if needed)

Summary

Strong position for value growth with Phase 3 development in a major medical indication: PTSD including military-related PTSD

- PTSD is an important public health issue

Tonmya for PTSD is designated as a Breakthrough Therapy by FDA

- Accelerated development and approval process is expected

Phase 3 HONOR study in military-related PTSD began enrollment in 1Q 2017

- Outcome of the interim analysis on ~275 randomized participants (50% efficacy evaluable) expected to be available 3Q 2018
- Completion of the 550-participant trial, if needed, and announcement of topline results expected in 4Q 2018
- NDA approval can be solely based on HONOR if the data are statistically persuasive

TONIX PHARMACEUTICALS

NASDAQ: TNXP

Thank you!

Exhibit 99.02

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer's Disease

FDA Official Minutes Support Tonix's Plan to File an IND in First Quarter 2018 for a Phase 2 Study

NEW YORK, December 11, 2017 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical and biological products to address public health challenges and diseases with significant unmet needs, announced today that it recently held a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposed development of TNX-102 SL*, the Company's patented sublingual tablet formulation of cyclobenzaprine hydrochloride (CBP) for bedtime use for the treatment of agitation in Alzheimer's disease (AAD). TNX-102 SL is currently in Phase 3 development for the treatment of posttraumatic stress disorder (PTSD).

Seth Lederman, M.D., President and Chief Executive Officer of Tonix, stated, "We are excited by our positive dialogue with FDA regarding the potential clinical utility of TNX-102 SL for agitation in Alzheimer's disease. Based on FDA's feedback, Tonix has the data needed to file an IND to support a potentially pivotal efficacy study. We plan to submit the TNX-102 SL IND for agitation in Alzheimer's disease in the first quarter of 2018."

Dr. Lederman continued, "We believe TNX-102 SL has the potential to treat agitation in Alzheimer's disease by improving sleep quality. It is anticipated that the development and approval of TNX-102 SL for agitation in Alzheimer's disease will benefit from the development program for PTSD. While initial NDA approval of TNX-102 SL for the treatment of PTSD, Tonmya®, remains our highest priority development program, we are also interested in exploring the clinical utility of TNX-102 SL in other indications and agitation in Alzheimer's disease is at the top of that list."

Dr. Gregory Sullivan, Chief Medical Officer of Tonix stated, "Agitation in dementia, dementia and moderate cognitive impairment are all associated with sleep disruption. The proposed sleep quality improvement mechanism of TNX-102 SL, coupled with its low dosage strength and bedtime dosing regimen makes it an ideal drug candidate to be investigated in agitation in Alzheimer's disease. The development of TNX-102 SL for agitation in Alzheimer's is part of our effort to investigate the proposed sleep quality improvement mechanism of TNX-102 SL in a number of established neuro-psychiatric disorders which are significant unmet needs."

*TNX-102 SL is an investigational new drug and has not been approved for any indication. Tonmya® has been conditionally accepted by the FDA as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for PTSD.

About Agitation in Alzheimer's Disease

Agitation in Alzheimer's disease is associated with significant negative consequences for both patients as well as their caregivers. Development of agitation, or its worsening, is one of the most common reasons for patients having to transition to nursing homes and other long-term care settings. Currently, there is no FDA approved treatment for behavioral symptoms such as agitation and aggression which affects the quality of life of both the patients and caregivers[1]. Sleep disturbances and agitation are common and co-morbid features of Alzheimer's disease.[2] Currently there is widespread off-label use of atypical anti-psychotic medications for behavioral symptoms in Alzheimer's disease, despite the lack of evidence for their effectiveness and significant risks associated with their use in this population.[3] Behavioral symptoms are a major clinical complication of Alzheimer's disease. They are estimated to be present in as many as 50 percent of community-dwelling patients, and as many as 80 percent of nursing home residents. Agitation, which includes emotional lability, restlessness, irritability, and aggression, is one of the most distressing and debilitating of these behavioral complications of Alzheimer's disease. Agitation is likely to affect more than half of the 5.3 million Americans who currently suffer from Alzheimer's disease, and this number is expected to nearly triple by 2050.[1] The presence of agitation nearly doubles the cost of caring for patients with Alzheimer's disease, and agitation is estimated to account for more than 12 percent of the $256 billion in healthcare and societal cost of associated with Alzheimer's disease for the year 2017 in the United States.[1]

[1]The Alzheimer's Association, 2017 Alzheimer's Disease Facts and Figures: https://www.alz.org/facts/
[2]Rose, K.et al. (2015). *American Journal of Alzheimer's Disease & Other Dementias*, *30*:78
[3]Greenblatt, H. K., & Greenblatt, D. J. (2016). *The Journal of Clinical Pharmacology*, *56*:1048

About TNX-102 SL

TNX-102 SL is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which provides rapid transmucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. The U.S. Patent and Trademark Office has issued a patent (U.S. Patent No. 9,636,408) protecting the composition and manufacture of the unique Tonmya formulation. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix's proprietary Tonmya composition. This patent is expected to provide Tonmya, upon NDA approval, with U.S. market exclusivity until 2034.

About Tonix Pharmaceuticals Holding Corp.

Tonix is developing innovative pharmaceutical and biological products to address major public health challenges and diseases with significant unmet needs. Tonix's lead product candidate, Tonmya, is in Phase 3 development as a bedtime treatment for PTSD. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but designed for daytime dosing. Tonix is also developing TNX-801, a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission (the "SEC") on April 13, 2017, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

Contacts

Jessica Morris
Investor Relations
investor.relations@tonixpharma.com
(212) 980-9159

Russo Partners (media)
Rich Allan
rich.allan@russopartnersllc.com
(646) 942-5588